Immunitybio, INC 8-K filings

ImmunityBio reports a 71% complete response rate in a 100-patient trial of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer, with durable responses up to 54 months.

ImmunityBio announced its third-quarter 2024 financial results, highlighted by ANKTIVA sales surpassing analyst estimates and progress in global regulatory submissions.

ImmunityBio settles a long-standing legal dispute, acquiring intellectual property and drug candidates related to its fusion protein platform.

ImmunityBio's annual meeting saw the re-election of all nine directors, approval of an increase in shares for the equity incentive plan, and ratification of the accounting firm.

The FDA has approved ImmunityBio's ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer, marking a significant advancement in immunotherapy.

ImmunityBio has approved discretionary bonuses for its top executives, established a new long-term incentive program, and updated its code of ethics.